NASDAQ:AURA Aura Biosciences Q1 2026 Earnings Report $6.00 -0.15 (-2.44%) Closing price 09/25/2026 04:00 PM EasternExtended Trading$6.00 +0.00 (+0.08%) As of 09/25/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Aura Biosciences EPS ResultsActual EPS-$0.50Consensus EPS -$0.40Beat/MissMissed by -$0.10One Year Ago EPSN/AAura Biosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAura Biosciences Announcement DetailsQuarterQ1 2026Date5/21/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsAura Biosciences' Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, November 11, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Aura Biosciences Earnings HeadlinesAura Biosciences, Inc.(NasdaqGM:AURA) added to S&P Biotechnology Select Industry IndexSeptember 21, 2026 | marketscreener.comMAura Biosciences, Inc. (AURA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 16, 2026 | seekingalpha.comReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.September 26 at 1:00 AM | Base Camp Trading (Ad)Aura Biosciences to Participate in Upcoming Investor ConferenceSeptember 2, 2026 | globenewswire.comAura Biosciences Grants Inducement Equity Awards to Newly Appointed ExecutivesSeptember 1, 2026 | quiverquant.comQAura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)September 1, 2026 | globenewswire.comSee More Aura Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Aura Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aura Biosciences and other key companies, straight to your email. Email Address About Aura BiosciencesAura Biosciences (NASDAQ:AURA) is a clinical-stage biotechnology company focused on developing precision oncology treatments that selectively target and destroy cancer cells while preserving healthy tissue. The company’s technology platform uses virus-like drug conjugates (VDCs) designed to bind to specific markers on tumor cells, deliver a therapeutic payload, and stimulate an immune response against the cancer. Aura’s lead product candidate is belzupacap sarotalocan, also known as bel-sar or AU-011. The investigational therapy is being developed as a localized treatment for primary choroidal melanoma, a form of eye cancer. Bel-sar is administered directly into the eye and activated with near-infrared laser light, with the goal of destroying tumor cells and promoting an immune-mediated response. Aura is also evaluating additional applications of its VDC platform in other solid tumors. Founded in 2009, Aura Biosciences is headquartered in Lexington, Massachusetts. The company is led by Chief Executive Officer Elisabet de los Pinos, Ph.D., and is advancing its programs through clinical development and research collaborations. Its primary focus remains developing targeted therapies for cancers that have limited treatment options, beginning with ocular oncology.View Aura Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/21 - 09/25Costco Ends Its Fiscal Year on a High Note, Eyes Big ExpansionCracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic ProblemDarden Restaurants Serves Up Fresh Catalysts for a Stock Price RallySoFi Is Bypassing the Banking Bottleneck With Stablecoin SettlementSuper Micro’s Vera Rubin Shipments Put Its AI Infrastructure Advantage to the TestHims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
